Cargando…

Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial

RATIONALE: Lower respiratory tract illness (LRTI) frequently causes adult hospitalization and antibiotic overuse. Procalcitonin (PCT) treatment algorithms have been used successfully in Europe to safely reduce antibiotic use for LRTI but have not been adopted in the United States. We recently perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Branche, Angela R., Walsh, Edward E., Jadhav, Nagesh, Karmally, Rachel, Baran, Andrea, Peterson, Derick R., Falsey, Ann R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820114/
https://www.ncbi.nlm.nih.gov/pubmed/27043012
http://dx.doi.org/10.1371/journal.pone.0152986
_version_ 1782425338683326464
author Branche, Angela R.
Walsh, Edward E.
Jadhav, Nagesh
Karmally, Rachel
Baran, Andrea
Peterson, Derick R.
Falsey, Ann R.
author_facet Branche, Angela R.
Walsh, Edward E.
Jadhav, Nagesh
Karmally, Rachel
Baran, Andrea
Peterson, Derick R.
Falsey, Ann R.
author_sort Branche, Angela R.
collection PubMed
description RATIONALE: Lower respiratory tract illness (LRTI) frequently causes adult hospitalization and antibiotic overuse. Procalcitonin (PCT) treatment algorithms have been used successfully in Europe to safely reduce antibiotic use for LRTI but have not been adopted in the United States. We recently performed a feasibility study for a randomized clinical trial (RCT) of PCT and viral testing to guide therapy for non-pneumonic LRTI. OBJECTIVE: The primary objective of the current study was to understand factors influencing PCT algorithm adherence during the RCT and evaluate factors influencing provider antibiotic prescribing practices for LRTI. STUDY DESIGN: From October 2013-April 2014, 300 patients hospitalized at a community teaching hospital with non-pneumonic LRTI were randomized to standard or PCT-guided care with viral PCR testing. Algorithm adherence data was collected and multivariate stepwise logistic regression of clinical variables used to model algorithm compliance. 134 providers were surveyed anonymously before and after the trial to assess knowledge of biomarkers and viral testing and antibiotic prescribing practices. RESULTS: Diagnosis of pneumonia on admission was the only variable significantly associated with non-adherence [7% (adherence) vs. 26% (nonadherence), p = 0.01]. Surveys confirmed possible infiltrate on chest radiograph as important for provider decisions, as were severity of illness, positive sputum culture, abnormal CBC and fever. However, age, patient expectations and medical-legal concerns were also at least somewhat important to prescribing practices. Physician agreement with the importance of viral and PCT testing increased from 42% to 64% (p = 0.007) and 49% to 74% (p = 0.001), respectively, after the study. CONCLUSIONS: Optimal algorithm adherence will be important for definitive PCT intervention trials in the US to determine if PCT guided algorithms result in better outcomes than reliance on traditional clinical variables. Factors influencing treatment decisions such as patient age, presence of fever, patient expectations and medical legal concerns may be amenable to education to improve PCT algorithm compliance for LRTI.
format Online
Article
Text
id pubmed-4820114
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48201142016-04-22 Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial Branche, Angela R. Walsh, Edward E. Jadhav, Nagesh Karmally, Rachel Baran, Andrea Peterson, Derick R. Falsey, Ann R. PLoS One Research Article RATIONALE: Lower respiratory tract illness (LRTI) frequently causes adult hospitalization and antibiotic overuse. Procalcitonin (PCT) treatment algorithms have been used successfully in Europe to safely reduce antibiotic use for LRTI but have not been adopted in the United States. We recently performed a feasibility study for a randomized clinical trial (RCT) of PCT and viral testing to guide therapy for non-pneumonic LRTI. OBJECTIVE: The primary objective of the current study was to understand factors influencing PCT algorithm adherence during the RCT and evaluate factors influencing provider antibiotic prescribing practices for LRTI. STUDY DESIGN: From October 2013-April 2014, 300 patients hospitalized at a community teaching hospital with non-pneumonic LRTI were randomized to standard or PCT-guided care with viral PCR testing. Algorithm adherence data was collected and multivariate stepwise logistic regression of clinical variables used to model algorithm compliance. 134 providers were surveyed anonymously before and after the trial to assess knowledge of biomarkers and viral testing and antibiotic prescribing practices. RESULTS: Diagnosis of pneumonia on admission was the only variable significantly associated with non-adherence [7% (adherence) vs. 26% (nonadherence), p = 0.01]. Surveys confirmed possible infiltrate on chest radiograph as important for provider decisions, as were severity of illness, positive sputum culture, abnormal CBC and fever. However, age, patient expectations and medical-legal concerns were also at least somewhat important to prescribing practices. Physician agreement with the importance of viral and PCT testing increased from 42% to 64% (p = 0.007) and 49% to 74% (p = 0.001), respectively, after the study. CONCLUSIONS: Optimal algorithm adherence will be important for definitive PCT intervention trials in the US to determine if PCT guided algorithms result in better outcomes than reliance on traditional clinical variables. Factors influencing treatment decisions such as patient age, presence of fever, patient expectations and medical legal concerns may be amenable to education to improve PCT algorithm compliance for LRTI. Public Library of Science 2016-04-04 /pmc/articles/PMC4820114/ /pubmed/27043012 http://dx.doi.org/10.1371/journal.pone.0152986 Text en © 2016 Branche et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Branche, Angela R.
Walsh, Edward E.
Jadhav, Nagesh
Karmally, Rachel
Baran, Andrea
Peterson, Derick R.
Falsey, Ann R.
Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial
title Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial
title_full Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial
title_fullStr Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial
title_full_unstemmed Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial
title_short Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial
title_sort provider decisions to treat respiratory illnesses with antibiotics: insights from a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820114/
https://www.ncbi.nlm.nih.gov/pubmed/27043012
http://dx.doi.org/10.1371/journal.pone.0152986
work_keys_str_mv AT brancheangelar providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial
AT walshedwarde providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial
AT jadhavnagesh providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial
AT karmallyrachel providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial
AT baranandrea providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial
AT petersonderickr providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial
AT falseyannr providerdecisionstotreatrespiratoryillnesseswithantibioticsinsightsfromarandomizedcontrolledtrial